WuXi Biologics (HKG: 2269), a leading Contract Research, Development, and Manufacturing Organization (CRDMO) based in China, has announced the successful installation of three sets of 5,000L single-use bioreactors at its drug substance manufacturing facility in Hangzhou (MFG20), which began operations in 2021. The installation of these bioreactors, compliant with Good Manufacturing Practice (GMP) standards, will increase the facility’s total capacity from 8,000L to 23,000L, thereby significantly enhancing the company’s manufacturing capabilities to better serve its global clientele.
Single-use bioreactors, as opposed to traditional stainless steel bioreactors, offer a highly flexible and cost-effective manufacturing solution. They are also considered more environmentally sustainable due to their reduced risk of contamination, making them a preferred choice in the biopharmaceutical industry.- Flcube.com
